Bioinformatics Intern
ZoetisFull Time
Entry Level & New Grad
New Brunswick, New Jersey, United States
Key technologies and capabilities for this role
Common questions about this position
The starting hourly compensation for this assignment is $43.00/hr. Please note that the final individual compensation and any applicable benefits will be determined by your employer of record (and not BMS).
The position is located in New Brunswick, NJ, and requires onsite work.
Candidates need experience in one or more of: computational modeling (e.g., fluid dynamics, discrete element modeling), machine learning (ML) and artificial intelligence (AI) applied to large datasets, pharmaceutical unit operations for parenteral or oral solid dosage forms, or medical device applications. They should also be highly motivated, self-driven, with innovative problem-solving ability and the ability to work independently and in teams.
BMS offers a challenging, meaningful, and life-changing work environment with uniquely interesting work, opportunities to grow alongside high-achieving teams, and a focus on balance and flexibility.
The program runs from Monday June 1, 2026 - Friday, August 7, 2026 (~10 weeks), where interns work with mentors on a guided research project within a PD Project Team, gaining industry experience and meeting company representatives.
Develops and delivers biopharmaceutical medicines
Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.